Product Description
Anamorelin is a ghrelin receptor agonist that can be administered orally and thought to improve cancer cachexia by improving appetite and increasing serum insulin-like growth factor-1.
Mechanisms of Action: GHS-R Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: European Medicines Agency | Japan
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location: Europe
Company Founding Year: 1976
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, China, Hungary, Italy, Romania, Russia, Serbia, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anorexia|Cachexia|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Weight Loss
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03743051 |
ANAM-17-20 | P3 |
Completed |
Cachexia|Anorexia|Non-Small-Cell Lung Cancer|Weight Loss |
2023-02-11 |
26% |
2024-06-28 |
|
2018-002926-22 |
2018-002926-22 | P3 |
Completed |
Weight Loss|Non-Small-Cell Lung Cancer|Anorexia|Small Cell Lung Cancer |
2023-02-11 |
26% |
2025-07-09 |
Treatments |
CTR20171102 |
CTR20171102 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer|Anorexia|Cachexia |
None |
2025-04-29 |